Dr.Kelly:2024 WCLC的主题是庆祝IASLC和IASLC会员50周年。我特意确保IASLC会员们都能领略部分庆祝活动，因为这次真的是为你们庆祝，是你们取得了这些惊人进步，对医生、患者和年轻研究人员进行教育，是你们付出了所有的努力，现在才出现了这些惊人的新疗法（包括手术、放疗、药物、筛查和诊断）。我真的强烈地感觉到，这次IASLC庆典必须以IASLC会员为主题，对所有IASLC会员表达欣赏和重视，这是50周年庆典活动的目标，我认为我们做到了，我们在这里度过了美妙的四天。

 

2024 WCLC的科学日程非常精彩，这才是推动WCLC的真正动力。伟大的科学进步激励人心，每个人都会欣然拥抱这些进步。2024 WCLC参会者充满热情，最重要的是一起庆祝IASLC成立50周年，你可以想象这里的气氛多么狂热。

 

Dr.Kelly:The theme this year has been about celebrating 50 years and celebrating our members.I made a point to make sure that members felt a part of the celebration，because we are really celebrating you.It is you who is making all of these wonderful discoveries and advances，and educating our physicians and patients and young researchers.It is you who is doing all the work to bring all of this to where we are today with amazing new therapies across surgery，radiation and drugs，but also screening and diagnosis.It is all of you.I really felt strongly that this conference had to be about you，and appreciating and valuing all of you as our members.That is really my goal，and I think we pulled it off.It has been an amazing four days here.

 

The science though has been incredible.That really drives the conference-when you have great science happening，it is motivating and passionate and everybody embraces it.There is enthusiasm，and then on top of that，to put a celebration of 50 years，my goodness gracious，you can just imagine how wild and crazy this place was.

 

Dr.Patel：2024 WCLC会议主题是庆祝IASLC在过去50年取得的进步，同时也思考为帮助患者IASLC还有哪些大量工作要做。至少在美国，癌症的总体死亡率在过去几年中有所改善，这主要得益于肺癌患者护理的改善，包括倡导戒烟、更好的筛查和治疗手段，合理使用新疗法，例如在局部晚期患者中应用靶向和免疫治疗，改善转移患者的治疗结局（免疫治疗可以治愈一些晚期患者），使用生存数据愈来愈持久的靶向治疗，以及为患者提供适当的姑息治疗和支持治疗。2024 WCLC的主题是确保我们全面满足癌症患者和癌症社区的需求，并在过去50年的基础上在肺癌领域更加有所作为，期待未来五十年IASLC的发展。

 

Dr.Patel:The theme is really celebrating the progress we’ve made in this organization over the past 50 years，but also thinking about the immense work we still have left to be done to help patients.The overall mortality from cancer，at least in the United States，has improved over the past several years driven predominantly by improvements in the care of patients with lung cancer.This includes everything from smoking cessation，to better screening and intervention，appropriate use of next-generation therapies such as targeted therapy and immunotherapy in the localized space，and improvements in the metastatic space where immunotherapy can cure some patients with advanced disease，and the use of targeted therapies which increasingly have durable efficacy，and the ability to also provide appropriate palliative and supportive care to patients and patient advocates.Making sure we are comprehensive in addressing the needs of cancer patients and the cancer community，and improving and increasing our activities in this area over the past 50 years is the theme of this year’s meeting.I am excited to see what the next 50 years will hold for this organization.

 

Dr.Patel：我认为2024 WCLC科学日程内容非凡，强大的IASLC成员队伍使WCLC收到大量优质摘要。我在这里将快速强调几项研究。

 

围绕HER2外显子20插入这个新靶点和EGFR PACC突变，WCLC进行了几次会议，表明肺癌精准医疗可以特别精确，仅仅确认患者有HER2或EGFR变异是不够的，还要进一步细分，因为针对HER2外显子20插入（SOHO-01研究）和EGFR PACC（FURTHER研究）有了靶向疗法。TROPION-Lung01研究采用定量连续评分（QCS）分析TROP2表达，以此来预测患者对靶向TROP2的抗体-药物偶联物（ADC）dato-DXd的疗效，这是肿瘤学领域首次基于人工智能（AI）的数字病理学解决方案为患者选择治疗方式。就像我们十年或二十年前谈论分子测序一样，我们将在未来几年讨论基于AI的数字病理学，这是首次展示该领域的数据。对比新辅助和围手术免疫治疗的CheckMate 77T和CheckMate 816患者水平数据分析非常有趣，此前没有研究回答围手术期免疫方案中术后治疗的贡献，所以这项研究数据非常好。HARMONi-2研究显示与PD-1单抗帕博利珠单抗相比，同时抑制PD-1/VEGF的依沃西单抗改善了驱动基因突变阴性晚期NSCLC多个高风险亚组的无进展生存（PFS），我们也热切地等待该研究中的总生存（OS）数据。

 

2024 WCLC展示了很多全球性研究，开展地域从欧洲到美国和加拿大，进行跨国专业合作，我认为这正是解决肺癌这种最复杂的科学难题所需要的。

 

Dr.Patel:I think it has been a phenomenal scientific program，and I want to congratulate the members of the society for having such strong faculty to attract such strong abstracts.I want to highlight a couple quickly.We had a couple of sessions around HER2 exon20 insertion，which is a novel target，and PACC mutations for EGFR，really showing that we can be particularly precise in precision medicine approaches.It is just not enough to say someone has a HER2 aberration or an EGFR aberration，but what is the specific molecular aberration now that we have targeted therapies.I think that is one aspect.We also had the use of artificial intelligence-based molecular pathology and digital pathology for the prediction of antibody-drug conjugate efficacy for TROP2 with datapotamab by using a QCS Score.This is the first time ever in oncology where we have an AI-based digital pathology solution for patient selection.Just like we were talking a decade or two ago about sequencing，we are going to be talking about AI-based digital pathology approaches for the years to come，and this is the first meeting to show data in that space.There were other really interesting abstracts on the neoadjuvant perioperative setting and comparing across studies，because there is no study that addresses the contribution of the backend component after surgery.So that is really nice data there.There was also some data around PD-1/VEGF combinatorial blockage with ivonescimab，which compared to pembrolizumab，had profound impacts on progression-free survival across multiple high-risk subgroups.We are eagerly awaiting overall survival data in that study as well.But a lot of global studies.These studies range from Europe to the United States and Canada and internationally employing expertise across countries.I think that is what it is going to take for us to tackle what is one the most complex scientific problems that is lung cancer.

 

Dr.Kelly:2024 WCLC有很多令人印象深刻的研究，比如周彩存教授介绍的HARMONi-2研究（比较依沃西单抗与帕博利珠单抗）确实非常令人印象深刻，表明我们可能已经突破了免疫疗法的瓶颈，这太棒了。我认为，对于HER2突变肿瘤患者，口服HER2靶向药的研究进展令人印象深刻（SOHO-01研究和Beamion LUNG-1研究）。针对其他分子靶点的研究也有令人印象深刻的数据，我可以继续说下去，重要内容太多了。

 

Dr.Kelly:I think there were many impressive studies.Of course，the HARMONi-2 study with ivonescimab versus pembrolizumab was really very impressive，presented by Dr Zhou，showing that maybe we have broken through the plateau of where we have been with immunotherapy.That is fantastic.I think to have oral medications for HER2 for patients whose tumors have HER2 mutations is impressive.Some of the other molecular targets were also impressive.I could go on and on and on.There were just lots of impressive things.